Search results
Showing 61 to 75 of 169 results for metastatic breast cancer
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
In development Reference number: GID-TA11342 Expected publication date: TBC
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued Reference number: GID-TAG403
Discontinued Reference number: GID-TAG387
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
In development Reference number: GID-TA11687 Expected publication date: TBC
Discontinued Reference number: GID-TAG391
Discontinued Reference number: GID-TAG432
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Discontinued Reference number: GID-TAG436
Discontinued Reference number: GID-TAG410
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for IPG785Show all sections